1 / 26

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients. Part 4 of 4. Incorporating SGLT2 Inhibitors into Practice:. Updates from EASD Mark W. Stolar, MD Associate Professor Clinical Medicine, General Internal Medicine and Geriatrics Feinberg School of Medicine

butlera
Télécharger la présentation

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients Part 4 of 4

  2. Incorporating SGLT2 Inhibitors into Practice: Updates from EASD Mark W. Stolar, MD Associate Professor Clinical Medicine, General Internal Medicine and Geriatrics Feinberg School of Medicine Northwestern University Chicago, IL

  3. SGLT2 Inhibitors: Use in Challenging or Special Populations • Non-insulin dependent mechanism of action allows for use in low insulin secreting or high insulin resistance type 2 diabetics • Safety/efficacy in older adults and /or renally impaired patients • Effects on weight, blood pressure and lipids

  4. Decision-MakingElementsin DeterminingA1CTargets MORE STRINGENT LESS STRINGENT Patient attitude and expected treatment efforts Highly motivated, adherent, excellent self-care capacities Less motivated, non-adherent, poor self-care capacities High Long-standing Short Severe Severe Limited RiskspotentiallyassociatedwithLow hypoglycemia, other adverse events Disease duration Newlydiagnosed Lifeexpectancy Long Importantcomorbidities Absent Established vascular complications Absent Resources,supportsystem Readilyavailable Hypotheticalpatient.Examplesare forillustrativepurposes only. AdaptedfromInzucchiSE,et al.DiabetesCare.2012;35(6):1364-1379.

  5. Decision-MakingElementsin DeterminingA1CTargets MORE STRINGENT LESS STRINGENT Patient attitude and expected treatment efforts Highly motivated, adherent, excellent self-care capacities Less motivated, non-adherent, poor self-care capacities High Long-standing Short Severe Severe Limited RiskspotentiallyassociatedwithLow hypoglycemia, other adverse events Disease duration Newlydiagnosed Lifeexpectancy Long Importantcomorbidities Absent Established vascular complications Absent Resources,supportsystem Readilyavailable Hypotheticalpatient.Examplesare forillustrativepurposes only. AdaptedfromInzucchiSE,et al.DiabetesCare.2012;35(6):1364-1379.

  6. Decision-MakingElementsin DeterminingA1CTargets MORE STRINGENT LESS STRINGENT Patient attitude and expected treatment efforts Highly motivated, adherent, excellent self-care capacities Less motivated, non-adherent, poor self-care capacities High Long-standing Short Severe Severe Limited RiskspotentiallyassociatedwithLow hypoglycemia, other adverse events Disease duration Newlydiagnosed Lifeexpectancy Long Importantcomorbidities Absent Established vascular complications Absent Resources,supportsystem Readilyavailable Hypotheticalpatient.Examplesare forillustrativepurposes only. AdaptedfromInzucchiSE,et al.DiabetesCare.2012;35(6):1364-1379.

  7. OminousOctet Reprintedwithpermissionfrom DeFronzoRA.Diabetes.2009;58:773-795.

  8. Increasedhepaticglucoseproduction Reduced peripheral glucose uptake Reduced pancreatic insulin secretion Insulin resistance Hyperglycemia Inhibition of glucose reabsorption from renal tubules Urinaryglucosedisposal Reduce fasting plasma glucose Improveglucosetolerance A1C reduction Urinary calorie loss/ Weight Loss AdaptedfromIdrisI, et al.DiabObes Metab.2009;11:79-88.

  9. EfficacyofSGLT2Inhibitorsin OlderAdults

  10. Efficacy of Canagliflozin in Older Adults: A1C and Weight Pooleddatafrom4 randomized,placebo-controlled,26-weekstudies(N=2,313) SinclairA, etal.Presentedatthe49thEASDAnnualMeeting;Barcelona,Spain;Sept,2013.Abstract955.

  11. EfficacyofCanagliflozininOlderSubjects:LipidandBPeffects Pooleddatafrom4 randomized,placebo-controlled,26-weekstudies(N=2,313) SinclairA, etal.Presentedatthe49thEASDAnnualMeeting;Barcelona,Spain;Sept2013Abstract955.

  12. PatientswithChronicKidney Disease

  13. Diabetes Therapy in the Setting of Impaired Renal Function • Metformin not indicated based on eGFR • Sulfonylureas should be used cautiously if at all due to hypoglycemic risk • TZD drugs are safe, but risk of edema increased with low • eGFR • DPP-4 inhibitors may require dosage adjustment • GLP-1 receptor agonists may require dosage adjustment • Insulin clearance is decreased, and risk of hypoglycemia is increased • SGLT2 inhibitors safe, but efficacy may be decreased

  14. Efficacy andSafetyofCanagliflozininPatientswith T2DM andChronicKidneyDisease:A1CandWeight NietoJ, etal. Presentedatthe49thEASDAnnualMeeting;Barcelona,Spain;Sept2013.Abstract951.

  15. Efficacy and Safety of Canagliflozin in Patients with T2DM and Chronic Kidney Disease: Lipid and Blood Pressure Effects NietoJ, etal. Presentedatthe49thEASDAnnualMeeting;Barcelona,Spain;Sept2013.Abstract951.

  16. ChangeinA1CwithCanagliflozininSubjectswithT2DMandStage3ChronicKidneyDiseaseChangeinA1CwithCanagliflozininSubjectswithT2DMandStage3ChronicKidneyDisease Pooled analysis in patients with T2DM from placebo-controlled studies with eGFR >30 and <60 mL/min/1.73m2 (n=1,085) and in subgroups with eGFR >45 and <60 (n=721) or > 30 and <45 (n=364). Data presented as Least Squares Mean (SE) change from baseline using ANCOVA and placebo-subtracted Least Squares mean (95% CI) values. † Mean baseline age 67 years; A1C 8.1%; eGFR 48.2; body weight 91 kg. ‡ Mean baseline age 66 years; A1C 8.1%; eGFR 53.3; body weight 90 kg; §Mean baseline age 66 years; A1C 8.1%; eGFR 38.2; body weight 92 kg. ¥ P < 0.001 vs placebo. P values reported for prespecified comparisons only. WooV,et al.PresentedatAmericanDiabetes2013ScientificSessions;Chicago,IL; June2013.Abstract73-LB.

  17. RecommendedDosing in PatientswithRenalImpairment Canagliflozin Dapagliflozin • Increase dose to 300 mg daily if eGFR • >60 mL/min/1.73 m2 • eGFR 45 to < 60 mL/min/1.73 m2: Limit dose to 100 mg daily • Do not initiate or discontinue if eGFR • < 45 mL/min/1.73 m2 • Do not initiate or discontinue if eGFR • < 60 mL/min/1.73 m2 Canagliflozin[packageinsert].Titusville,NJ: JanssenPharmaceuticals;2013. Dapagliflozin[packageinsert].Princeton,NJ: Bristol-MyersSquibbCompany;2014.

  18. ChangesinLipid Profileswith SGLT2 Inhibitors

  19. ChangesinLipidProfilesof PatientsonDapagliflozin Plasmalipidchangesfrombaseline(%,95%CI)inpooledDAPAstudiesat24weeks 12phase2b/3double-blind, controlledtrials forupto24weekswereanalyzed.(n=3,731) HardyE, etal.Presentedatthe49thEASDAnnualMeeting.Barcelona,Spain.Sept2013.Abstract947.

  20. WeightLossandBlood PressureEffects

  21. Dapagliflozin-inducedWeightLossAffects24WeekA1CandBloodPressureLevelsDapagliflozin-inducedWeightLossAffects24WeekA1CandBloodPressureLevels ∆ BW,kg -5 -4 -3 -2 -1 0 0 Effectofother 14% 17% variables Added benefit of weight loss during dapagliflozin treatment that contributes to overall changes in A1C and to changes in blood pressure after 24 weeks of treatment -1 37% -2 Effect of ∆ In BW 49% ∆SBP,mmHg -3 46% -4 Non-BW ∆ related -5 37% treatmenteffect Dapagliflozin10mg -6 Placebo -7 SjöströmCD, etal. Presentedatthe49thEASDAnnualMeeting.Barcelona,Spain.Sept2013.Abstract181.

  22. Canagliflozin Lowers A1C Through Weight Loss–Independent and Weight Loss–Associated Mechanisms RelationshipbetweenchangesinA1Candbodyweightatweek26* 0.2 0 -0.2 -0.4 -0.6 -0. -1.0 -1.2 -1.4 Placebo Canagliflozin 100 mg Canagliflozin 300 mg ∆ A1C(%) Weightloss- independent Weight loss- associated Most (85%) of the A1C-lowering effect of canagliflozin is independent of weight loss -10 -5 0 5 ∆ body weight (%) Across all 3 treatment groups, subjects with greater weight loss had greater reductions in A1C, and the slope associated weight loss for A1C was similar across all 3 groups. Each 1% reduction in BW was associated with a 0.045% reduction in A1C. *Solid symbols represent mean changes within each decile of weight change, and open symbols are mean changes in the entire treatment group. Pooled analysis of 4 previously reported, randomized, double-blind, 26-week, phase 3 studies (N=2,250). Wilding L, et al. Presented at the 49th EASD Annual Meeting. Barcelona, Spain. Sept 2013. Abstract 946. Reproduced with the permission of Janssen Research & Development, LLC

  23. Canagliflozin Lowers A1C Through Weight Loss–Independent and Weight Loss–Associated Mechanisms Relationshipbetweenchangesinsystolic bloodpressureandbodyweightatWeek 26* 6 4 2 0 -2 -4. -6 -8 -10 Placebo Canagliflozin 100 mg Canagliflozin 300 mg ∆SBP(mmHg) Weight loss contributes to ~40% of the SBP-lowering effect of canagliflozin -10 -5 0 5 ∆ body weight (%) In each treatment group, subjects with greater weight loss had greater reductions in systolic blood pressure, with similar slopes associated with weight loss observed across all 3 groups. Each 1% reduction in body weight was associated with a 0.62% mm Hg reduction in systolic blood pressure. *Solid symbols represent mean changes within each decile of weight change, and open symbols are mean changes in the entire treatment group. Pooled analysis of 4 previously reported, randomized, double-blind, 26-week, phase 3 studies (N=2,250). Wilding L, et al. Presented at the 49th EASD Annual Meeting. Barcelona, Spain. Sept 2013. Abstract 946. Reproduced with the permission of Janssen Research & Development, LLC

  24. Effects of Dapagliflozinon Body Weight Placebo + Metformin Dapagliflozin 10 mg + Metformin 0.5 1.0 -0.5 -1.0 -1.5 -2.0 -2.5 -3.0 -3.5 -4.0 Changeintotalbodyweight (kg)* LOCF Differencefrom placebo -2.08kg (95%CI-2.84, -1.31) P<0.0001 0 4 Samplesizepertime point 8 16 Study Week 24 Baselinevalue(kg) Dapagliflozinreducestotalbody weightpredominantly by reducingfatmass,visceral adiposetissueandSCadiposetissuevolume. Reprintedwithpermissionfrom BolinderJ, et al. J ClinEndocrinolMetab.2012.97(3):1020–1031.

  25. EffectsofDapagliflozinonRegionalAdiposeTissueDistribution Meanchangefrom baselineinVATandSATvolumewithtreatmentat 24wk Placebo + Metformin n=42; n=37 Dapagliflozin 10 mg + Metformin n=37; n=30 200 Change in adipose tissue volume(cm3) 0 -39.2 -121.4 -200 -297.5‡ -400 -306.4§ -600 VisceralAT SubcutaneousAT -800 Dapagliflozinreducestotalbody weightpredominantly by reducingfatmass,visceral adiposetissueandSCadiposetissuevolume. ‡, VAT, -258.4 cm3 (95 CI = -448.1 to -68.6; nominal P = 0.0084); §, SAT, -184.9 cm3 (95% CI = -359 to -10.1; nominal P = 0.0385). Reprintedwithpermissionfrom BolinderJ, et al. J ClinEndocrinolMetab.2012.97(3):1020–1031.

  26. Summary • SGLT2 inhibitors are effective therapies in challenging patient populations • Efficacy of these therapies is reduced in older adults and renally impaired patients, but safety is maintained • Beneficial effects on weight and blood pressure are consistently seen, but clinical impact remains to be determined • Minor changes in LDL-C, but not HDL-C or triglycerides, • are observed • – Minor changes in non-HDL-C with canagliflozin • Cardiovascular outcome studies are in progress

More Related